The specialty prescription drugs market is predicted to develop 8 % yearly via 2025, in response to a report by Shields Health Solutions, leaving $118 billion for grabs available in the market.
Health programs are projected to seize 25 %, or $29.5 billion, of that market progress.
The variety of specialty pharmacies grew 315 % to 1,570 specialty pharmacies in 2021 within the U.S., from simply 378 in 2015, in response to the 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers by the Drug Channels Institute. And hospitals are shortly getting on board, now proudly owning a couple of third of specialty pharmacies — as a result of they’re profitable.
In 2019, solely 4.9 % of commercially insured sufferers took specialty medication, however made up about 50 % of all drug spending that yr.
But hospital-owned specialty pharmacies are inefficient, Jankowski stated.
“Because of the costs associated with specialty drugs, insurers want a lot of info and, meanwhile, because these drugs are given to usually a very sick patient, a lot of monitoring needs to occur,” Jankwoski stated. “If the insurers is going to pay $18,000 for an injection, we need to make sure the patient should require this injection and ensure they are physically able to take the injection and when they should take it.”
However, there was no software program to handle all the information, leaving pharmacists to handle the affected person load, insurer requests and knowledge monitoring individually.
“These drugs used to be a niche but have become a focused class and the emergence and maintenance of specialty pharmacies grew alongside the rise of these drugs,” Jankwoski stated. “But there’s never been a good software to manage the difficulty in administering these drugs. Pharmacists have to check your medical record, maybe take diagnostics and provide a lot of info the payer. We can monitor that in once place now.”
Jankowski stated due to streamlined data monitoring, the DromosPTM system additionally offers pharmacies with most popular entry to specialty medication that may typically be arduous to supply.
“Drug companies want a lot of data,” Jankowski stated. “DromosPTM can provide that data and because the supply is controlled by the drug companies, you have a better chance of giving them the data and, thus, receiving the supply using the software.”